Medicare Pays for Home Immune Globulin — Until the Pump and the Drug Don't Match

A neurologist refers a CIDP patient who has been on IVIg in the infusion suite for fourteen months and responded well. The plan is to move her to a subcutaneous product she can run at home twice a week. Everyone is on board. The prior authorization is not required. The drug is on formulary. The pump is in stock.

Seven months later the remittance comes back denying the pump line and the drug line on the same claim, and the person reading it assumes the diagnosis was the problem. It usually isn't. On home IG the four things that most often end a claim are a product label, a pairing table, a modifier, and a date. None of them are clinical.

Five criteria, and two of them are about the product, not the patient

Subcutaneous immune globulin sits at indication V, situation H of LCD L33794. It is covered when criteria 1 through 3 are met, and criterion 4 or criterion 5:

• 1. The SCIg preparation is a pooled plasma derivative that is FDA-approved.
• 2. The SCIg is administered in the home.
• 3. The treating practitioner has determinedthat administering SCIg in the patient's home is medically necessary and appropriate.
• 4. The beneficiary has a primary immune deficiency disorder; or
• 5. The beneficiary has CIDP that has responded to IVIg treatment.

Criterion 3 is the one intake teams underestimate. It is not satisfied by the order, and it is not satisfied by a supplier-generated form that the practitioner signs. The determination has to be the practitioner's, about this patient's home, and it has to be findable in the practitioner's own record. A reviewer pulling the chart wants to see a clinician who thought about whether home administration was appropriate here — not a checkbox that migrated in from a fax cover sheet.

Criterion 5 has a second half that gets dropped constantly. CIDP alone is not the qualifying condition. CIDP that has responded to IVIgis. So the file needs prior IVIg therapy and a documented response to it. "Patient has CIDP, starting Hizentra" is a sentence that describes a plan and proves nothing. A reviewer is looking for the earlier IVIg course and a clinical note saying it worked.

"CIDP is not the coverage criterion. CIDP that responded to IVIg is. Every file we read that skips the second half reads to a reviewer like an unqualified diagnosis."

Coverage stops at the label

The LCD says it in one line and it costs suppliers a great deal of money: coverage of subcutaneous immune globulin applies only to products specifically labeled for subcutaneous administration. Intravenous immune globulin products are not covered under this LCD at all.

That sounds obvious until you look at what actually happens in practice. A patient stable on an IVIg product transitions to home therapy. The prescriber writes for the molecule they know. The pharmacy dispenses what is on the shelf. And what ships is an IV-labeled product being run subcutaneously, which is clinically defensible in some hands and outside this benefit entirely. There is no route modifier that fixes it, because the problem is the FDA label on the vial, not the route on the claim.

The pairing table nobody in the building has read

Policy Article A52507 contains a table that assigns each SCIg preparation to specific pump codes. It runs three rows. It has no clinical content. And the LCD attaches the harshest consequence in the policy to it: if a drug and pump combination is used other than those listed in the table, the pump and the drug will both be denied as not reasonable and necessary.

Two rows there are worth memorizing. Hizentra on an E0781 is a denial. HyQvia on an E0779 is a denial. Both are easy mistakes for a warehouse to make, because the pumps are interchangeable from a clinical standpoint and a coordinator picking one off the shelf is thinking about the patient's dexterity and the infusion volume, not about which HCPCS code the pharmacy is going to bill next to it.

The E0779 definition matters here too. It is a reusable mechanical pump that must be capable of a single infusion cycle of at least eight hours. Its near-twin, E0780, is the same device with a cycle under eight hours, and E0780 appears nowhere in the SCIg pairing table. If someone codes E0780 because the infusion runs ninety minutes, that is not a more accurate code. It is an unlisted combination, and the drug goes with it.

Two modifier rules, and only one of them is famous

The KX, GA and GZ logic on external infusion pumps works the way it does everywhere else in DME, with a deadline attached. For claims submitted on or after March 1, 2023, a claim line billed without KX, GA or GZ is rejected as missing information. No appeal, just a line somebody has to find. Rejected, not denied. There is nothing to appeal. The line comes back, somebody has to notice it on a report, and the correction joins a queue.

KX is an attestation that every coverage criterion in the LCD has been met and the evidence is in your files. On a home IG claim, appending KX asserts that the product is subcutaneously labeled, that the practitioner determined home administration was appropriate, that the diagnosis is PI or IVIg-responsive CIDP, and that the pump matches the drug. If any of that is thin, GA with a properly executed ABN is the honest choice and GZ is what you use when there is no valid ABN.

The less famous rule is JB, and it is specific to this therapy. Where the route of administration is subcutaneous, a JB modifier must be added to each HCPCS code:

• Immune globulins J1551, J1555, J1558, J1559, J1561 and J1569 and the associated E0779 pump claim.
• Immune globulins J1551, J1558 and J1575 and the associated E0781 pump claim.

Each HCPCS code. Not the drug line only. Teams that append JB to the drug and leave the pump line bare are producing a claim that does not describe a subcutaneous therapy, which is the only version of this therapy the LCD covers.

HyQvia has a rule about how the device leaves your dock

HyQvia is administered through a pre-programmed E0781, and the policy article is explicit: the pump must be delivered to the beneficiary in locked mode, meaning the patient cannot self-adjust the infusion rate. This is an operational requirement that lands on a delivery technician, not on a biller.

It is also the kind of requirement that leaves no trace unless someone deliberately creates one. If your delivery record does not show that the pump was programmed and locked, then months later, when a contractor asks, the answer is whatever the technician remembers. Add a line to the proof-of-delivery form. It costs nothing and it is the only evidence that will exist.

"A file can contain a perfect diagnosis, a responsive prior IVIg course and a supportive neurologist, and still deny — because the pump on the claim line was not the pump the policy pairs with that vial."

Supplies bring their own denials

Codes A4221, A4222 and K0552 are the non-insulin supply codes, and they are valid only with E0779, E0780, E0781, E0791 or K0455. Billed with E0784 — the insulin pump — for dates of service on or after January 1, 2017, they are incorrect coding. The reverse also holds: A4224 and A4225 belong to the insulin pump and are not billable with the non-insulin pumps.

• A4221 covers catheter-site maintenance supplies. It is payable during covered pump use and for the weeks in between covered use, capped at four weeks per episode.
• A4222 is the cassette or bag with diluting solutions, tubing, administration supplies, port cap changes, and compounding and preparation charges. Allowance is based on the number of cassettes or bags actually prepared.
• K0552 is the syringe-type reservoir. It is not separately payable when the infusion drug is pre-packaged and supplied in a syringe-type cartridge, which describes most of the SCIg market.
• An IV pole (E0776) is covered only with a stationary E0791 pump. Billed alongside an E0779 or E0781, it is not reasonable and necessary.

For continuous infusions the policy expects the concentration and container size to be maximized so the fewest bags, cassettes or syringes are used. That is a utilization rule that reads as a clinical preference and functions as an audit trigger.

And the order still has to come first

External infusion pump codes fall under Final Rule 1713, which means the face-to-face encounter and written order prior to delivery requirements in the Standard Documentation Requirements article apply. The line that matters is this one: if a supplier delivers before receiving the WOPD, the item is denied as not reasonable and necessary, and obtaining the WOPD afterward does not repair it. Payment will not be made for that item, ever, on that delivery.

Home IG referrals are exactly the kind that outrun their own paperwork. The patient is transitioning off an infusion suite, there is a gap in therapy, the prescriber is responsive but slow to sign, and somebody makes the humane decision to get the pump into the home this week. That decision is correct for the patient and it forfeits the claim.

How the sequence actually has to run

What this asks of one coordinator

Count what a single home IG referral requires somebody to verify. Five coverage criteria, one of which lives in a physician's note at another organization. An FDA label check on a vial the pharmacy selected. A pairing table lookup that connects a drug HCPCS to a pump HCPCS. A diagnosis that has to carry its own treatment history with it. A written order whose date must precede a delivery date. A device that has to leave the dock in a particular software state. Two modifier systems, one of which rejects rather than denies. And a supply-code family check that turns on which pump went out the door.

That is one referral, on a patient who genuinely needs the therapy, handled by a coordinator who has eleven other files open and a fax queue that does not stop. None of these teams are careless. They are running a multi-document compliance review by hand, on a therapy where the clinical case is so clear that the paperwork feels secondary. The consequence shows up seven months later as two denied lines nobody can trace back to the decision that caused them.

Reading the file against the rule before it goes out is the whole job. That is the part DocuFindr automates.